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Following the mutation screening of genes 
known to cause amyotrophic lateral sclerosis 
(ALS) in index cases from 107 familial ALS 
(FALS) kindred, a point mutation was 
identified in vesicle associated membrane 
protein-associated protein B (VAPB) or 
VAMP-associated protein B causing an amino 
acid change from threonine to isoleucine at 
codon 46 (T46I) in one FALS case but not in 
257 controls. This is an important finding as it 
is only the second mutation identified in this 
gene that causes ALS. In order to investigate 
the pathogenic effects of this mutation, we have 
used a motor neuron cell line and tissue 
specific expression of the mutant protein in 
Drosophila. We provide substantial evidence 
for the pathogenic effects of this mutation in, 
abolishing the effect of wild-type VAPB in the 
unfolded protein response, promoting 
ubiquitin aggregate formation and activating 
neuronal cell death. We also report that 
expression of the mutant protein in the 
Drosophila motor system induces aggregate 
deposition, ER disorganization and chaperone 
up regulation both in neurons and in muscles. 
Our integrated analysis of the pathogenic effect 
of the T46I mutation and the previously 
identified P56S mutation indicate extensive 
commonalities in the disease mechanism for 
these two mutations. In summary, we show 
that this newly identified mutation in human 
FALS has a pathogenic effect supporting and 
reinforcing the role of VAPB as a causative 
gene of ALS.  
 
    
Amyotrophic lateral sclerosis (ALS) is a common 
degenerative disease causing muscle weakness and 
atrophy, paralysis and bulbar symptoms, which 
eventually leads to death due to respiratory failure 
within three to five years of symptom onset. ALS 
is caused by loss of motor neurons and a 
characteristic pathological feature of the disease is 
the presence of ubiquitinated inclusions containing 
TDP-43. The mechanism whereby the disease 
specifically affects motor neurons is unclear and 
current therapy is limited in effectiveness. Major 
advances have occurred recently with the 
identification of mutations causing the familial 
form of ALS (FALS), which is clinically 
indistinguishable from the sporadic form (SALS), 
accounts for approximately 5% of cases and shares 
the same pathological features (1). Mutations in 
seven genes are known to give rise to FALS, 
superoxide dismutase (SOD1), vesicle-associate-
membrane-protein-associated protein B (VAPB), 
senataxin, alsin, dynactin, TDP-43 and FUS, 
which has shed light on the importance of 
oxidative stress, the unfolded protein response 
(UPR), protein aggregation and abnormal RNA 
processing in the pathogenesis of ALS (see 
reviews: (2-4). Multiple mutations have been 
described for all these genes with the exception of 
VAPB, where only one missense mutation (P56S) 
has been reported to date, being present in seven 
Brazilian kindred exhibiting clinically diverse 
phenotypes, including ALS and late-onset Spinal 
Muscular Atrophy (5,6). No other VAPB 
mutations have been identified in sporadic ALS 
(SALS) or other ALS populations (7,8) until now, 
where we report a second VAPB mutation and 
further provide evidence for its pathogenic effects.  
 VAPB is a member of the VAP family, 
which includes VAPA, an established regulator of 
vesicle trafficking (9-11). VAPB plays a role in 
the UPR, which is activated when misfolded 
proteins accumulate in the endoplasmic reticulum 
(ER) (12,13). VAPs are also known to control 
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lipid metabolism and lipid transfer between the ER 
and other organelles by interacting with proteins 
such as oxysterol binding proteins (OSBP), Nir 
proteins, ceramide transfer protein (CERT) and 
Opi1 (14-18). In Drosophila, DVAP-33A (DVAP) 
controls the number and size of boutons at the 
neuromuscular junction. Furthermore, loss of 
DVAP disrupts the synaptic microtubule 
cytoskeleton (19) causing an increase in miniature 
junctional potential amplitudes and postsynaptic 
glutamate receptor clustering (20).  
 In this study, we have demonstrated 
pathogenic actions of this novel VAPB mutation, 
promoting the formation of ubiquitinated 
aggregates, activating cell death pathways and 
leading to the generation of a robust motor 
phenotype in vivo in larval neurons, adult eye and 
neuromuscular junction of Drosophila. We have 
further developed a model of disease through the 
integration of our findings with those already 
reported for the P56S-VAPB mutation. 
 
EXPERIMENTAL PROCEDURES 
 
Sequencing- A cohort of 185 FALS kindred was 
used for this analysis. Patients and families were 
referred by general practitioners and physicians 
and the diagnosis of ALS was carried out 
according to the El Escorial World Federation of 
Neurology criteria for Diagnosis of ALS with 
evidence of both upper and lower motor neuron 
involvement. The mean age at death of patients 
lacking SOD1 mutations was 55.6 years (CI: 54.3 
to 56.9 years; n = 389) and mean disease duration 
was 3.3 years (CI: 2.7 to 3.9; n = 193) (21). In our 
study we used 110 FALS cases from this cohort, 
where DNA was available, in search of additional 
mutations in VAPB. The sequencing reaction was 
carried out with a total of 50 ng of DNA and 
amplified using primers listed in supplemental 
Table 1. PCR products were purified using a 
Nucleospin extraction kit (CLONTECH) and 
eluted in 20 l of molecular grade water 
(SIGMA). The purified PCR products were 
sequenced using a forward or reverse primer and 
the ABI Prism
TM
 BigDye
TM
 terminator kit. DNA 
sequencing was carried out using an ABI 377 
automatic sequencer.  
Molecular Cloning of wild-type and mutant 
VAPBs into GFP and RFP vectors- To generate 
the full length VAPB fragment, the PCR was 
performed using 5’ and 3’ VAPB primers 
(GCCAAAGGTGCTCCGCCGC and 
CTACAAGGCAATCTTCCC) with a VAPB 
template purchased from OriGene. This fragment 
was cloned into pcDNA3.1/NT-GFP-TOPO 
(Invitrogen) via TA cloning, which produced a N-
terminal GFP fusion protein. For generating the 
RFP fusion VAPB, additional restriction enzyme 
cutting sequences of Eco RI (GAATTC) and Bam 
HI (GGATCC) were placed at the 5’ end of VAPB 
5’and 3’ primers respectively. The PCR product 
was cloned into pCR2 (Invitrogen) via TA cloning 
and then sub-cloned into pDsRed2-C1 (Clontech) 
via EcoRI/Bam HI. To introduce the mutations, a 
traditional two-step mutagenesis PCR was 
performed as described in supplemental data. The 
sequences of all PCR products were verified by 
sequencing. 
Transfection and immunocytochemistry- COS-7, 
N2a and NSC-34 cells were cultured in DMEM 
medium containing 10% FBS and were seeded the 
day before transfection. Cells were transfected 
using Lipofectamin 2000 (Invitrogen) according to 
the manufacturers protocol. To establish VAPB 
stable expression cell lines, NSC-34 cells were 
transfected with either wild-type (WT) or T46I-
VAPB and were selected in 10% FBS containing 
DMEM plus 400 μg/ml of G418 (Invitrogen). 
For immunocytochemistry staining, cells 
were lysed with RIPA buffer, except for the 
solubility analysis, which was carried out as 
described by Kanekura et al. (12). Protein 
concentration was determined using the Bio-Rad 
protein assay kit (Bio-Rad). Proteins were 
separated with 10% SDS-PAGE and blotting was 
carried out using conditions specified for the 
antibodies. For immunofluorescence studies, cells 
were fixed in 4% paraformaldehyde for 30 min at 
room temperature and permeabilised for 30 min in 
0.1% Triton X-100 in PBS. Nuclei were stained 
with 0.5 μg/ml DAPI in PBS for 10 min. PBS 
washes were applied between reagent changes. 
After the final staining and wash, cover slips were 
mounted onto slides using Fluorsave reagent 
(Calbiochem), and left to dry at 4°C overnight.  
Antibodies for immunocytochemistry or 
immunofluorescence- Rabbit polyclonal anti-GFP 
(1:3000, Abcam); rabbit polyclonal anti-ubiquitin 
(1:200, Dako); rabbit polyclonal anti-phospho-
eIF2α (1:1000, Cell signaling), anti-β-actin 
(1:25000, Sigma); peroxidase labeled goat anti-
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rabbit IgG (1:1000, Vector); Alexa Fluor 594 goat 
anti-rabbit IgG (1:2000,Invitrogen).                                                                                                     
Cell death analysis- NSC-34 cells were 
trypsinised, washed with ice-cold PBS twice, and 
stained using the Annexin V: PE apoptotic 
detection kit (BD Bioscience) according to the 
manufacturer’s protocol. The cells were then 
analysed with a fluorenscence-activated cell 
sorting (FACS) flow cytometer (BD Bioscience). 
VAPB SNP typing- DNA was amplified using 20 
ng of genomic DNA, 1.5 mM of MgCl2, 0.5 μM 
of forward and reverse primers, 1X PCR buffer 
and 1.25 u of Platinum Taq (Invitrogen). PCR was 
performed using 94°C for DNA denaturing, 58°C 
for annealing and 72°C for extension. Restriction 
enzymes producing different cutting patterns 
according to SNP status were used to genotype 
each SNP. Different size fragments were then 
separated by electrophoresis using a 1.5 to 2.2% 
agarose gel. The primer sequences and enzyme 
used for each SNP are listed in supplemental Table 
1. DNA was extracted from the aqueous phase of 
TRIZOL homogenates (22) as described in 
supplemental data.  
Fly genetics and molecular techniques- Flies were 
raised on standard media at 25°C. To assess the 
effect of T48I mutation in neurons and muscles, 
UAST48I-DVAP/UAST48I-DVAP transgenic males 
were crossed to elav-GAL4 (23) and BG57-GAL4 
(24) females respectively. For temperature pulses, 
to induce a higher expression of the GAL4 protein, 
flies of the relevant genotypes were left to mate at 
room temperature for 24 h, then the parents were 
removed and the progeny was shifted to 30°C in a 
water bath.  Site directed mutagenesis on DVAP 
cDNA was performed using the Quick Change 
Site Directed Mutagenesis Kit (Stratagene). 
Transgenic UAS lines were made by cloning the 
DVAP cDNA carrying the T48I mutation into the 
PUAST vector (25). Constructs were injected into 
the embryonic germ cells and transgenic lines 
were established following standard procedures.  
Cell transfections and immunocytochemistry- Full-
length T48I-DVAP and DVAP ORFs constructs 
were generated by PCR and cloned into Myc- and 
Flag-tagged pCMV expression vectors 
respectively. COS-7 cells were cultured in DMEM 
medium containing 10% FCS and 1% 
penicillin/streptomycin. COS-7 cells were seeded 
on Poly-D-Lysine Coated glass coverslips (BD 
BioCoat) at a concentration of 150,000 cells/ml. 
The day after, cells were transfected with 
Transfection Reagent (Roche) according to 
manufacturer's instructions. 24 h later, cells were 
fixed in 4% paraformaldehyde for 20 min and 
blocked in PBT containing 10% normal goat 
serum (NGS). Staining with the relevant 
antibodies was performed accordingly to the 
procedure described in the Immunocytochemistry 
section. Rabbit anti-myc (Sigma) and mouse anti-
Flag (Sigma) primary antibodies were used at a 
concentration of 1:500 and 1:200 respectively. 
Secondary antibodies (Jackson ImmunoResearch) 
were all used at a concentration of 1:500.      
Scanning electron microscopy and eye histology- 
Eyes were fixed in 3% glutaraldehyde, in 0.1M 
sodium cacodylate buffer pH 7.3, for 2-3 h, and 
further processed and analysed as described in 
supplemental data.  
Microscopy and morphological quantification- To 
acquire the 2D images for processing, the bodies 
were photographed using a digital camera attached 
to an Olympus stereomicroscope and processed as 
described in supplemental data. Quantification of 
the eye phenotype was performed using the 
Oculus v1.0 software.  Oculus v1.0 is a tool 
written in MATLAB, which was developed in-
house to aid measurement of the size of the adult 
fly eyes. Unlike the shape selection tools provided 
in image processing software such as ImageJ 
(available at http://rsb.info.nih.gov/ij; developed 
by Wayne Rasband, National Institutes of Health, 
Bethesda, MD), the Oculus v1.0 software 
presented each image at a zoomed-out level and 
permitted the border of the eye to be traced pixel-
by-pixel: this method encouraged detailed 
examination of the boundary and therefore 
increased the precision of the delineation. 
Subsequent automated validation operations 
ensured the highlighted path was closed and 
skeletonised (26-28) so the outline could be saved 
to a database. The area of each eye was then 
measured using a flood-fill operation in these 
enclosed regions and the number of pixels counted 
was inserted into a spreadsheet for further 
analysis. 
Immunohistochemistry- Body wall muscles from 
wondering third instar larvae were dissected and 
stained accordingly to Chai et al., (20). The 
following primary antibodies were used:  rabbit 
polyclonal anti-HRP at 1:200 (Jackson 
ImmunoResearch), guinea pig polyclonal anti-
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DVAP at 1:1000 (19), mouse monoclonal anti-
KDEL at 1:50 (Stressgene), mouse monoclonal 
anti-Hsp70 at 1:200 (Affinity Bioregents), rabbit 
polyclonal anti-SERCA antibody at 1:1000, guinea 
pig polyclonal anti-Boca antibody at 1:1000. For 
the co-staining with the anti-Boca antibody, a rat 
polyclonal DVAP antibody was used at 1: 1000 
(19). Secondary antibodies (Jackson 
ImmunoResearch) were all used at a concentration 
of 1:500.   Fixed and labelled larvae were imaged 
with a Zeiss LSM510 confocal microscope with a 
63/1.4 objective. Single high-resolution images 
were acquired as stacks of images with separate 
channels and processed with the LSM software or 
Adobe Photoshop and Adobe Illustrator. 
Statistics- One-way ANOVA test was used to 
compare multiple conditions in an experiment. 
Bonferroni’s multiple comparison test was used as 
a post-test when significance was found in 
ANOVA test. In the fly studies, statistical analysis 
was performed using the two-tailed Student's t-test 
to compare the test genotype to controls. Error 
bars are SE. Single SNP allele frequency and 
genotype frequency p-values were obtained using 
the Fisher exact test 
(http://www.quantitativeskills.com/sisa/). The EH 
programme was used to test linkage disequilibrium 
between SNPs and to compare the difference of 
pairwise haplotype frequency between groups. The 
six SNP haplotype was constructed from the 
population genotyping data by the PHASE 
programme (v2.1), which also gave a p-value of 
the haplotype frequency difference between 
groups (29,30). BIMBAM24 was used to evaluate 
the association between the genotypes and the 
phenotype (31), which, in our case, were SNP 
haplotype and VAPB expression level. Mantel-
Haenszel Common Odds Ratio was obtained from 
SPSS stats package to evaluate the association of 
overall major/minor allele with VAPB expression 
level. 
 
   
RESULTS 
 
Identification of a new ALS-associated mutation in 
VAPB, T46I-VAPB. All six coding exons of VAPB 
plus flanking intronic regions were sequenced in 
107 index cases of FALS kindred of UK origin 
that lacked mutations in SOD1, TDP-43 and FUS. 
A point mutation causing an amino acid change 
from threonine to isoleucine at codon 46 (T46I) 
was identified in one FALS case presenting with 
typical ALS but not in 257 healthy controls (Fig. 
1A). The index case with the amino acid 
substitution in VAPB was diagnosed with classical 
ALS. Signs at onset revealed on first examination 
at the age of 73 years, included wasting of the 
small muscles of the right hand. There were 
fasciculations in the left vastus medialis and both 
gastrocnemii. Plantars were flexor. Sensation was 
normal whereas speech and swallowing 
difficulties developed at the age of 75 years. The 
diagnosis was confirmed by nerve conduction 
studies. The patient had a brother with ALS who 
died within 4 months of diagnosis from 
bronchopneumonia. There were no further DNA 
samples available from this family, as the patient 
had no children. DNA was not available from any 
other affected members of this family and this 
mutation was not found in any of the other FALS 
cases screened or in 257 control subjects 
(Caucasian which matched the index case). 
Interestingly this mutation together with the 
previously identified P56S mutation causing ALS8 
is located in a stretch of 16 amino acids that 
appears to be highly conserved throughout species 
(Fig. 1B, C). We have therefore carried out a range 
of functional studies in cell culture and in vivo to 
elucidate the potential pathological effects of this 
mutation that it shares with the known ALS-
associated mutation P56S and to further elucidate 
novel aspects of their mechanisms of disease. 
Cellular distribution of T46I and the formation of 
insoluble aggregates.  Since studies of the ALS-
causing mutation, P56S-VAPB, in cell culture 
have shown that the mutant protein forms 
insoluble cytosolic aggregates, and is able to 
interact with wild type (WT) VAPB and VAPA 
(12,13,32) affecting the function of the WT 
protein, we tested whether the T46I mutation 
affected the sub-cellular distribution of the protein. 
In order to examine the effect of this amino acid 
substitution on VAPB protein distribution and 
solubility, GFP tagged wild-type VAPB (WT-
VAPB), T46I-VAPB and P56S-VAPB constructs 
were generated and expressed in COS-7 cells. The 
typical ER localisation pattern of a web-like 
distribution within the cytosol extending from the 
nuclear surface was shown for the WT-VAPB 
construct, whereas both T46I-VAPB and P56S-
VAPB constructs produced VAPB protein 
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aggregates within the cells (Fig. 2A) as previously 
reported for P56S-VAPB (6,12,32). However, 
there was greater variance in the distribution of 
T46I-VAPB, which showed different degrees of 
aggregation ranging from small granules to large 
coalesced structures with some cells showing a 
normal ER distribution. The same distribution 
patterns were found following transfection with 
these constructs in two neuronal cell lines, the 
neuroblastoma cell line, N2a and the spinal cord 
motor neuron cell line, NSC-34 cells 
(supplemental Fig. 1). This marked effect on 
aggregation was also clearly demonstrated by a 
shift in distribution from the Triton X-100 soluble 
fraction of cell lysates to the insoluble fraction 
(Fig. 2B, C) compared to WT-VAPB, as 
previously shown for P56S (12). Although T46I-
VAPB showed a different impact on VAPB 
protein distribution when compared with the P56S 
mutation, both mutations affected protein 
solubility to a similar extent (Fig. 2B, C). This 
result further supported the observation that both 
T46I and P56S mutations triggered VAPB protein 
aggregation. 
T46I-VAPB is unable to activate the IRE1 
pathway. Although VAPB is highly localized to 
the ER, its actions in ER function are less well 
characterised. However, a well-documented 
function of VAPB is its ability to potentiate the 
IRE1 pathway, a component of the UPR, which is 
disrupted by the P56S-VAPB mutation (12,13). In 
order to characterise the role of VAPB in the 
IRE1/XBP1 pathway, an XBP1-Venus construct 
was used as a reporter of IRE1/XBP1 activation 
(33). Under normal conditions, the mRNA for the 
transcription factor, XBP1, contains a premature 
stop codon, and thus produces an immature protein 
with short half-life. When cells are under ER 
stress, the activated IRE1 causes the splicing of 
XBP1 mRNA into a mature mRNA, which in turn 
produces the functional transcription factor. Based 
on the nature of this alternative RNA splicing, 
Iwawaki et al. developed an ER stress reporter by 
fusing a fluorescent protein, Venus, to XBP1, 
which can only be expressed when the IRE1-
mediated splicing takes place (33). Thus, the 
presence of the fluorescence indicates the 
activation of IRE1. 
 RFP tagged WT-VAPB, T46I-VAPB and 
P56S-VAPB constructs were generated and co-
transfected with the XBP1-Venus reporter into 
NSC-34 cells. The presence of the reporter in RFP 
positive cells was quantified for each construct 
using flow cytometry. Further, the effect of WT 
and mutant VAPBs on the response to the ER 
stress inducer, tunicamycin (TN), which is known 
to inhibit N-linked glycosylation, was also 
investigated.  
 WT-VAPB showed a clear induction of 
IRE1 activity, increasing 9-fold above the vector 
control after 24 h transfection, which effect was 
enhanced in the presence of TN (ANOVA p = 
0.001, 0.0035 respectively: Fig. 3A, B). This 
property was significantly impaired in both T46I- 
and P56S-VAPB expressing cells (p < 0.001: Fig. 
3A). The inhibitory effect of T46I was stable, 
yielding a reduced activation (50%) at 48 hours 
after transfection, compared to WT-VAPB (p < 
0.05). Upon TN treatment, a partial response was 
seen with T46I-VAPB but this was not significant.  
 In a second series of experiments, we used 
NSC-34 permanent cell lines stably expressing 
WT-VAPB or T46I-VAPB protein transfected 
with RFP-VAPB expression construct and XBP1-
Venus to determine whether mutant VAPB 
interfered with the ability of WT-VAPB to 
activate this pathway. Although the expression of 
WT-VAPB in this stable cell line substantially 
induced IRE1/XPB1 activation, transfection with 
WT-VAPB significantly increased the magnitude 
of Venus induction (Fig. 3C). However, in T46I-
VAPB stable cells, transfection with WT-VAPB 
was not able to induce IRE1/XBP1 activation (Fig. 
3C), which indicated that endogenous T46I-VAPB 
may interact with and prevent exogenously 
expressed WT-VAPB from promoting IRE1/XBP1 
activation.  Taken together, this result suggested 
that T46I-VAPB not only lost the ability to 
activate IRE1 pathway efficiently, but also was 
able to inhibit the action of the wild type protein.  
 The activation of another ER stress sensor 
present in the ER membrane, PERK, was also 
investigated. This pathway is involved in the 
regulation of translational suppression and the 
induction of certain ER chaperone proteins, which 
are mediated in part through the phosphorylation 
of eIF2alpha (34). We monitored the 
phosphorylation of eIF2alpha in response to the 
fast acting ER stress inducer thapsigargin (TG), 
which acts by increasing cytosolic calcium 
concentration through inhibiting intracellular 
calcium pumps (supplemental Fig. 2), and 
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compared the response of VAPB expressing cells 
to untransfected and vector transfected cells (Fig. 
3D, E). However, phosphorylation of eIF2 was 
not significantly modified in the presence of either 
wild type or mutant VAPBs, using either 
transiently transfected or permanent cell lines (Fig. 
3D, E). Taken together, these data show that 
VAPB protein activates the unfolded protein 
response by acting through the IRE1/XBP1 
pathway and that the VAPB protein containing the 
newly identified T46I mutation lacks this property.  
Ubiquitin aggregation is triggered by mutant 
VAPB. The presence of ubiquitin-positive 
aggregates is a widely used marker of the 
progression of neurodegenerative diseases, which 
occurs in ALS and the G93A-SOD1 mouse model 
of ALS. To investigate whether the expression of 
mutant VAPB triggered the formation of 
ubiquitin-positive aggregates, NSC-34 cells were 
transiently transfected with GFP-VAPB 
constructs, immunostained for endogenous 
ubiquitin and cells containing ubiquitin-positive 
aggregates were quantified for each genotype. 
Ubiquitinated aggregates were abundant in both 
T46I- and P56S-VAPB expressing cells compared 
to WT-VAPB expressing cells, whilst GFP-
transfected cells contained few or no aggregates 
(Fig. 4A). A similar increase in the proportion of 
cells expressing either T46I or P56S-VAPB 
compared to WT-VAPB was observed (ANOVA p 
= 0.0047) (Fig. 4B). The number of ubiquitin-
positive cells expressing WT-VAPB was similar to 
that seen in the vector control (Fig. 4B).  
 Previous studies of mutant SOD1 have 
suggested that a non-cell autonomous effect 
occurs, which may be a consequence of secretion 
of the mutant protein (35,36), and in order to 
determine whether this is relevant to VAPB, which 
is known to be secreted in a truncated form in 
Drosophila (20,37,38) we also analysed the effect 
of VAPB expressing cells on the formation of 
ubiquitinated aggregates in the neighbouring GFP 
negative cells. Indeed, we found a significant 
effect due to T46I-VAPB (ANOVA p = 0.022) 
(Fig. 4C), which suggests that mutant VAPB 
expressing cells secrete a factor that can influence 
these neighbouring cells. A similar non-significant 
trend was seen for P56S-VAPB expressing cells 
(Fig. 4C). No VAPB protein was detected in the 
culture medium from the mutant transient 
transfections (data not shown), in agreement with 
a previous study (37). This result suggests that, 
whatever the cause, non-cell autonomous toxicity 
does not act through secreted mutant VAPB. In 
summary, these data show that T46I-VAP induces 
the formation of ubiquitinated aggregates. 
Surprisingly, a significant increase in the 
ubiquitin-positive clusters were observed in 
untransfected neighbouring cells suggesting a 
possible non-cell autonomous effect of the mutant 
protein expressing cells on surrounding cells.    
The expression of T46I-VAPB leads to cell death. 
Although the UPR initially plays a cytoprotective 
role, when the stress is prolonged, a switch from 
this pro-survival program to a pro-apoptotic 
program, occurs in which a number of pro-
apoptotic proteins, such as caspase-12 (rodents) 
and caspase-4 (man), are activated leading to cell 
death (34). We therefore investigated whether the 
presence of mutant VAPB proteins activated 
apoptosis by measuring the appearance of both 
early and late apoptotic markers. We first looked 
at the presence of Annexin V on the cell 
membrane, an early apoptotic marker, using 
permanent cell lines. A marked increase in the 
number of Annexin V-positive cells expressing 
T46I-VAPB compared to cells expressing the wt 
protein was found, as shown by the flow 
cytometry profiles (Fig. 5A). When quantified, 
this increase was highly significant (Fig. 5B). We 
also examined the appearance of 7-AAD, a late 
apoptotic marker. In this case as well, we observed 
that the expression of the mutant protein was 
accompanied by a significant increase in the 
number of 7-AAD-positive cells when compared 
to cells expressing WT-VAPB (Fig. 5B p = 
0.0045). In order to assess the effect of the mutant 
protein on WT-VAPB, a co-culture was set up, in 
which the permanent cell line expressing WT-
VAPB was co-cultured with the same number of 
cells expressing T46I-VAPB.  The total number of 
cells in the co-culture was the same as that in the 
single cultures (total = 3,000 cells in each 
condition). Although only half of the cells in the 
co-culture expressed T46I-VAPB, a significantly 
increased number of annexin V-positive cells were 
detected (ANOVA = p = 0.0004, Fig. 5C). This 
suggested that T46I-VAPB interacted with WT-
VAPB promoting apoptosis. 
Transgenic expression of the mutant protein in 
Drosophila larval neurons induces the formation 
of aggregates. In order to get further insight into 
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the effect of the T46I-VAPB mutation in ALS 
pathogenesis, we turned to Drosophila, an 
organism, proven to provide a model for VAP-
induced ALS (20,37,38). The threonine at position 
46 in humans corresponds to threonine at position 
48 in Drosophila VAP (T48I-DVAP)(Fig. 1C). 
DVAP cDNA containing the T48I mutation was 
generated by site-directed mutagenesis and sub-
cloned into Drosophila transformation vectors 
(UAST48I-DVAP). Several independent transgenic 
lines were established and the mutant transgenes 
were expressed by using the UAS/GAL4 system 
(25). In Drosophila, the UAS/GAL4 system 
allows the temporal and tissue-specific expression 
of a transgene by using a variety of GAL4 drivers 
(25). We targeted the expression of UAST48I-
DVAP in larval neurons by using the pan-neural 
driver elav-GAL4 (23).   
 As VAPB aggregates have been clearly 
demonstrated for this mutation in cell culture (see 
above) and for the P56S mutation in flies (20), we 
assessed whether the accumulation of inclusions 
containing the protein causing the disease is also 
common to T48I-DVAP-induced pathology. We 
performed confocal analysis on larval brains and 
nerve fibres of T48I-DVAP transgenic larvae 
stained with antibodies specific for DVAP. In WT 
flies, DVAP is distributed underneath the cell 
membrane and in the cytoplasm of neuronal cell 
bodies (Fig. 6A-C) where an extensive 
colocalization with ER specific markers is 
observed (Fig. 6D-F). In contrast, neurons of 
transgenic larvae expressing T48I-DVAP are filled 
with brightly fluorescing inclusions of variable 
sizes (Fig. 6G, H). In control nerves, VAP 
immunoreactivity is uniformly distributed, while 
in T48I-DVAP nerves, numerous massive 
aggregates are visible (compare Fig. 6I and 6J). 
This phenomenon was consistently observed in all 
transgenic lines examined. Conversely, several 
lines expressing the WT-DVAP protein at similar 
or higher levels do not show the formation of 
aggregates (data not shown) (20). Taken together 
these data indicate that transgenic expression of 
DVAP-T48I in neurons induces the formation of 
intracellular inclusions brightly immunoreactive 
for DVAP.  
Targeted expression of T48I-DVAP in the adult 
eye causes neuronal degeneration. To assess the 
potential role of T48I-DVAP toxicity in neurons 
other than motor neurons, we targeted the 
expression of T48I-DVAP in the nervous system 
of adult flies. This would allow us to study the 
progression of the phenotype on the temporal axis, 
as the life span of an adult fly is much longer than 
that of a larva. When the T48I-DVAP transgene 
was expressed into the adult brain by using the 
elav-GAL4 driver, flies of the correct genotype 
failed to hatch. This early death phenotype is 
consistent with a severe loss of integrity of the 
nervous system. We then targeted the expression 
of T48I-DVAP transgene in the eye using the 
eyeless-GAL4 driver, as adult vision is not 
required for viability (39,40). T48I-DVAP 
transgenic lines exhibited an abnormal eye 
phenotype upon eclosion. As compared to 
controls, the eyes expressing the T48I-DVAP 
transgene were reduced in size and displayed a 
rough phenotype over the entire surface. Analysis 
using scanning electron microscopy (SEM) 
revealed disorganized and fused ommatidia with 
missing, irregular and occasional supernumerary 
mechano-sensory bristles (Fig. 7A-D).  Paraffin 
sections of the heads of T48I-DVAP transgenic 
flies confirmed loss of cells beneath the external 
surface of the eyes. Photoreceptor morphology 
was severely disrupted and several vacuoles were 
visible (Fig. 7E, F). Vacuolization has been 
observed in several fly models of 
neurodegenerative diseases and the appearance of 
these vacuoles has been correlated to 
neurodegeneration (41-43).     
 Another important aspect of the T48I-
DVAP-induced eye phenotype seen in adult flies 
is the fact that the size of the eye exhibits a 
significant degree of heterogeneity in the severity 
of the phenotype. We performed a detailed 
quantification of the eye size in both mutants and 
controls by using Oculus v1.0, a MATLAB 
software recently developed in our lab (see 
Experimental Procedure for a detailed description 
of this software). The distribution of the eye size 
was measured over a cohort of at least 25 flies 
carrying the T48I-DVAP transgene. Eye sizes from 
a similar number of control flies were also 
measured. The majority of the mutant flies (65%) 
possessed eye sizes between 1000 and 2000 
arbitrary square units, whilst the remaining flies 
exhibited a larger size ranging between 2000 and 
2500 square units. Control flies on the other hand 
have eye sizes centred between 4000 and 4750 
square units (Fig. 7G, H). Overall the eye size in 
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T48I-DVAP transgenic flies is less than 50% of 
the size of controls (Fig. 7H, p < 0.0001). 
 Although the accumulation of aggregates 
strongly immunoreactive for T48I-DVAP was 
evident in transgenic animals expressing the 
mutant protein in neurons (Fig. 6), the pattern of 
expression of the WT protein was no longer 
detectable (compare Fig. 6G with 6H and 6I with 
6J). To test whether the mutant protein can recruit 
the WT protein into the aggregates, we co-
transfected COS-7 cell lines with plasmids 
encoding a Flag tagged version of DVAP and a 
MycT48I-DVAP plasmid. The subcellular 
localization of both proteins was determined by 
using tag-specific antibodies. In COS7 cells 
transfected with DVAP, the protein forms a 
perinuclear reticular staining as expected for an 
ER-associated protein (Fig. 8A). When COS-7 
cells were cotransfected with both Flag-DVAP and 
MycT48I-DVAP, a diffuse punctuate staining 
reminiscent of the aggregates present in cell 
bodies and motor fibers of T48I-DAVP transgenic 
larvae, was observed (Fig. 8B-G). Interestingly, 
the staining of the WT and the mutant proteins 
perfectly overlap indicating that both proteins are 
components of the intracellular inclusions (Fig. 
8B-G). 
Transgenic expression of T48I-DVAP in larval 
brains causes ER fragmentation and heat-shock 
protein up-regulation. As reported above for the 
expression of the mutant protein in motor neuron 
cell lines, expression of the same protein in 
Drosophila neurons induces cell degeneration and 
accumulation of aggregates both in cell bodies and 
in nerves. We also showed that the accumulation 
of misfolded proteins in the aggregates triggers an 
UPR response in cell culture. In Drosophila, the 
UPR pathway is not well characterized due, at 
least in part, to the fact that the UPR genes are 
essential during development (44). We therefore 
investigated whether other neuropathological 
features that are usually associated with the UPR 
response were present in our fly model.   
 The presence of aggregates in the form of 
intracellular inclusions containing the disease 
causing protein is thought to arise from the 
unfolding or misfolding of the same protein. 
Protein folding occurs in the cytoplasm or within 
the lumen of the ER. In the ER a specialized set of 
chaperones and components of quality control 
machinery ensures correct folding. Interestingly, 
structural abnormalities in the ER characterized by 
ER fragmentation and Golgi cisternal dilation has 
been reported in motor neurons of brain stem and 
spinal cord of patients affected by sporadic ALS 
(45). To assess whether such a neuropathological 
feature is also common to T48I-DVAP-induced 
ALS, we stained T48I-DVAP transgenic brains 
with an anti-KDEL antibody, a marker specific for 
ER resident proteins. In controls, the anti-KDEL 
staining detects a reticular, perinuclear pattern as 
expected for a marker highlighting the ER (Fig. 
8H-J). In transgenic brains, the staining appeared 
fragmented and dispersed throughout the cell (Fig. 
8K-M). Occasionally the staining was found to co-
localize with the aggregates immunoreactive for 
DVAP (data not shown). This phenotype was 
confirmed by using an antibody specific for the 
Boca protein (46), another independent ER marker 
(supplemental Fig. 3).  
 Affected tissues in neurodegenerative 
diseases often exhibit the induction of a chaperone 
stress response. Heat shock protein induction has 
been reported in a mouse model with widespread 
mutant SOD1 expression (47) and chaperones 
have been found to be associated with SOD1 
inclusions in motor neurons (47-49). Recent data 
suggest that up-regulation of Hsp70 is beneficial 
to disease progression in mouse models of ALS 
(50). Brains of transgenic larvae expressing T48I-
DVAP were stained with an anti-Hsp70 antibody. 
In control brains, Hsp70 staining was faint and 
spread throughout the cytoplasm of neurons 
whereas in the transgenic brains, clusters of 
specific immunoreactivity was observed. These 
clusters are closely associated but do not overlap 
with DVAP aggregates (Figure 8N-S). In 
summary, as already reported for the first P56S-
DVAP fly model (20,37,38), targeting the 
expression of T48I-DVAP in neurons induces 
aggregate formation, cell degeneration, ER 
fragmentation and up-regulation of chaperone 
proteins.   
The skeletal muscle is a direct target of T48I-
DVAP mediated toxicity. The advantage of using 
an intact organism as a model for human diseases 
is that it allows the study of the effect of a 
pathogenic mutation in different cell types. 
Alterations in skeletal muscles during ALS have 
been considered to result from toxicity of the 
mutant protein in motor neurons rather than a 
direct effect of the same protein on muscle cells. 
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In order to explore whether skeletal muscle is a 
direct target for T48I-DVAP mediated toxicity, we 
generated transgenic flies in which the DVAP 
mutant gene was selectively expressed in skeletal 
muscles. To this end, the BG57-GAL4 line was 
used as GAL4 expression in this line is under the 
control of a muscle-specific enhancer (51). We 
first assessed the presence of DVAP in larval 
skeletal muscles and its specific sub-cellular 
localization within the muscle. Dissected NMJs 
were stained with a range of muscle specific 
markers. As expected from previous studies, we 
observed DVAP immunoreactivity to be 
distributed throughout the cytosol of the muscle 
(32,52). The staining appears to be concentrated 
around the nuclei of the muscle syncytium largely 
co-localizing with SERCA, a calcium ATPase, 
associated with the sarco-endoplasmic reticulum 
of the muscle (53)(Fig. 9A-F). 
 As already observed for transgenic 
expression of the mutant allele in neurons, the 
expression of the same protein in muscles using 
BG57-GAL4 driver, induced the formation of 
large aggregates strongly immunoreactive for 
DVAP (Fig. 9K, Q). In the same lines, 
fragmentation of the ER was also observed when 
the transgenic flies expressing T48I-DVAP 
specifically in muscle were stained with an 
antibody specific for Boca, an ER marker in 
Drosophila (46) (Fig. 9J). In controls, 
however,anti-Boca staining of muscles exhibited a 
reticular and perinuclear pattern (Fig. 9G). 
Interestingly, immunostaining of transgenic 
muscles with both anti-DVAP and anti-Boca 
antibodies showed that DVAP-positive aggregates 
extensively colocalize with the fragmented ER 
(Fig. 9L). This phenotype was confirmed by using 
SERCA, another independent ER/Sarcoplasmic 
reticulum marker (data not shown).  
 In many neurodegenerative diseases 
including ALS, aggregates are thought to be 
formed from the accumulation of misfolded 
proteins that trigger the up-regulation of chaperone 
proteins. We assessed whether this was also the 
case for muscles expressing T48I-DVAP. In 
controls, Hsp70 protein is very low and almost 
under the detection limit of our antibody (Fig. 9M-
O). In transgenic animals expressing T48I-DVAP 
specifically in skeletal muscles, there is an 
increase in the expression levels of Hsp70 that 
appears to concentrate in puncta mainly localized 
to the nucleus (Fig. 9P-R). Although the 
phenomenon of relocation of Hsp70s to the 
nucleus is still poorly understood, it is clear that 
this relocation is directly linked to cellular stress 
(54,55). Similar results were observed when a 
P58S-DVAP transgene expressing the other 
DVAP mutation causing ALS8 in humans was 
targeted to the muscle using the BG57-GAL4 
driver (data not shown).    
Genotype correlations with VAPB expression in 
SALS. In view of our previous observation that the 
expression of VAPB is significantly decreased in 
SALS spinal cord compared to controls (22), we 
investigated whether VAPB SNP variants were 
associated with the level of expression of VAPB in 
spinal cord in this large cohort of cases previously 
described (22). Since there are no reported 
functional SNPs in the coding region or splice 
sites, we chose SNPs that are close to exon 
boundaries, which might also detect 
uncharacterised functional variants. The six SNPs 
selected for this study were rs6026230T/C, 
rs6026256T/G, rs2234487C/G, rs2234489G/A, 
rs6100067C/T and rs1802459A/G, and their 
locations within the gene are shown in Fig. 10A. A 
total of 63 samples composed of 21 healthy 
controls and 42 ALS were genotyped and divided 
into normal (n=36) and low (n=27) expression 
groups. Normal levels of expression were defined 
by the 90% confidence intervals (CI) of the control 
group which contained 19 out of 21 of control 
cases. 60% of the ALS cases were outside this CI. 
Two groups were formed using this threshold, 
group 1 contained samples with normal expression 
(90% CI of control group) and group 2 contained 
samples with low expression and was composed of 
27 samples including 24 SALS, 1 FALS and 2 
controls. 
 A significant difference in allele frequency 
for SNP rs6100067 was found between normal 
and low VAPB expression (Fig. 10B) using both 
the Fisher exact test (p=0.029) and the BIMBAM 
program (p=0.026). The rare allele was more 
abundant in the group with normal VAPB 
expression levels compared to the group with low 
VAPB expression levels, which suggests that this 
SNP has a beneficial effect preventing decreased 
VAPB gene expression. Although no significant 
association was found between expression levels 
and the other SNPs per se, there was a consistent 
trend in which the rare allele frequencies of all six 
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SNPs were lower in the low VAPB expressing 
samples compared to the normal expressing group 
(Fig. 10B). Indeed, a significant linkage was found 
using the Mantel-Haenszel test, which indicates 
that these six VAPB SNPs show an overall 
association of major allele with VAPB low 
expression (p<0.0001, the Mantel-Haenszel 
common odds ratio = 2.04). The two-SNP 
haplotype was then constructed and examined by 
the EH program and only the rs6026230- 
rs6100067 haplotype was found to be significantly 
different between the two expression groups 
(p=0.047) where the C-T haplotype was decreased 
by 14% in the low expression group. Despite the 
fact that this SNP has no known function and is 
outside regulatory regions involved in RNA 
splicing, it may be linked to a functional sequence 
variant which is responsible for the VAPB 
expression difference.  
 
DISCUSSION 
 
In this study we report the identification of a novel 
mutation in VAPB, which is not only the second 
mutation in VAPB to be found associated with 
FALS but is the first to be found in a non-
Brazilian kindred. Evidence for the pathogenic 
effect of this mutation is provided using motor 
neuron cell lines and motor system-targeted 
expression in Drosophila. We have shown for the 
first time that mutant VAPB causes cell death and 
that this T46I mutant protein in turn affects 
neighbouring cells that do not express the mutant 
protein. Furthermore, we reported a substantial 
down-regulation of VAPB mRNA in SALS spinal 
cord (22) and in this study we have shown a SNP 
association with levels of expression, suggesting 
that VAPB is widely involved in ALS 
pathogenesis, which is further borne out by studies 
in G93A-SOD1 transgenic mice (32). 
VAPB and ER stress. ER stress is a well-
established feature of ALS (1,56) and the 
discovery of ALS associated mutations in VAPB, 
a key component of this response, highlights the 
importance of this essential response in neuronal 
survival. Early studies showed that the yeast 
homolog VAP, Scs2, restored inositol auxotrophy 
IRE1/Hac1 mutant cells (57,58), which implies a 
role for VAP in lipid transfer and/or synthesis and 
sheds light on the crosstalk between VAP and 
IRE1/XBP1.The latter was also verified in 
mammalian systems, where VAPB triggers the 
cleavage of XBP1, an initial signal for IRE1 
activation (12,13). The ALS-associated mutations 
in VAPB, T46I and P56S, abolish the ability of 
WT-VAPB to activate IRE1/XBP1, as shown in 
this study. Furthermore, both P56S-VAPB and 
T46I-VAPB cause a redistribution of wild type 
protein trapping it in VAPB inclusions in 
mammalian cells and Drosophila (this study and 
20,37) and due to their tendency to form 
heterodimers with WT-VAPB, they may also 
prevent WT-VAPB from fulfilling its role during 
the UPR (12,13). The results presented here 
support the hypothesis that affected motor neurons 
fail to activate a functional UPR to counteract ER 
stress, which if prolonged, leads to cell death (Fig 
11). 
 The detailed mechanism whereby VAPB 
participates in UPR is still unclear. There is as yet 
no evidence showing a direct interaction between 
VAP and IRE1 or XBP1 (59). However, the key 
amino acid residues involved in the trafficking of 
lipid-associated proteins mediated by the FFAT 
(two phenylalanines in an acidic tract) domain, 
such as CERT, OSBP and Nir (14,16), are 
contained in a highly conserved 16 amino acid 
region containing T46 (Fig. 1). It has been 
proposed that this FFAT binding domain coincides 
with the domain necessary for UPR activation via 
IRE1/XBP1 (13). Although, the P56S mutation 
would not be expected to affect FFAT binding by 
itself (60), it still prevents IRE1 activation (12). It 
was recently demonstrated that P56S obstructs 
FFAT binding through enhancing VAPB 
oligomerisation and thus decreases accessibility to 
the VAPB binding domain (61). Therefore, the 
inability of mutant VAPB to activate IRE1/XBP1 
could be a result of the mutations per se, or could 
be the effect of protein conformational changes 
imparted by the mutation, as is the case for FFAT 
binding.  
 This is the first study in which the activation 
of the PERK pathway has been monitored in 
VAPB expressing cells and no significant effect of 
VAPB and VAPB mutations was detected on the 
level of phosphorylated eIF2. However, we 
found that high levels of phosphorylated eIF2 
could be detected 30 minutes to 2 hours after TG 
treatment in NSC-34 cells and thereafter decreased 
to undetectable levels at 6 h suggesting that the 
phosphorylation of eIF2 is a rapid and short-term 
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response which is then switched off upon the 
prolonged stressed condition. Therefore we cannot 
exclude the possibility that VAPB mutations may 
have rapid and transient effects on the PERK 
pathway.  
 We have also shown that the expression of 
T46I-VAPB in NSC-34 cells or T48I-DVAP in 
flies causes cell death without any further 
challenge. An earlier report did show that P56S-
VAPB reduced cell viability in NSC-34 cells but 
only after thapsigargin treatment (13). This 
difference may reflect the fact that we are using 
permanent expression systems in vitro and in vivo.  
 Emerging evidence indicates that the 
pathogenesis of many neurodegenerative diseases 
including ALS, involves a non-cell autonomous 
process but the mechanism mediating the transfer 
of toxicity between cells is still unclear (1). 
Interestingly, chromogranin-associated mutant 
SOD1 is secreted into the extracellular milieu and 
induces microgliosis and neuronal cell death 
(35,36). Here we report that the co-culture of WT- 
and T46I-VAPB expressing cells results in much 
greater cell death compared to T46I alone. This 
observation, together with the finding that 
untransfected cells cultured with mutant VAPB 
transfected cells are more likely to contain 
ubiquitinated aggregates than controls, suggests 
that mutant VAPB expressing cells are able to 
affect neighbouring cells that, whilst not 
producing the mutant protein themselves, become 
stressed and eventually undergo cell death. In 
Drosophila, the N-terminal MSP domain of 
DVAP is secreted and may act as a ligand of the 
Eph receptor and the P58S mutation in DVAP, 
equivalent to the human P56S mutation in VAPB, 
inhibits the ability of the WT protein to be 
secreted (37,62). However, as we have been 
unable to recover any VAPB fragments from the 
culture medium, it is still undetermined whether 
the non-cell autonomous effect is caused by 
VAPB directly or by the release of other factors 
triggered by VAPB.  
 The effect of the newly identified mutation 
on cellular processes known to play a role in 
neurodegeneration, such as UPR, accumulation of 
ubiquitinated aggregates and cell death were 
studied in cell lines. In a parallel and 
complementary approach, we used the Drosophila 
model system to assess in vivo effects relevant 
ALS mechanisms. More specifically, the 
contributions of different tissues and systems 
(peripheral motor system, muscle and central 
nervous system) to the pathogenic effects induced 
by the novel mutation were investigated in our 
Drosophila model.  
 Previous studies have established 
Drosophila as a suitable model system to study 
VAP-induced ALS. In particular, a wealth of 
experimental evidence indicates that hVAPB and 
DVAP are functionally interchangeable both in 
loss-of-function and over-expression paradigms. 
First, many of the fundamental biochemical 
properties of hVAPB including its ability to 
oligomerize and to interact with lipid binding 
proteins are conserved in DVAP (20,63). 
Secondly, transgenic expression of DVP carrying 
the ALS causing mutation, recapitulates many of 
hallmarks of the human disease (20,37,38 and this 
work). Furthermore, expression of human VAPB 
in a mutant background for DVAP fully rescues 
the lethality, the morphological and the 
electrophysiological phenotypes associated with 
DVAP loss-of-function mutations (20,37). Taken 
together, these results strongly indicate that 
Drosophila is an excellent model organism to 
investigate both the WT function of VAP proteins 
and their role in ALS pathogenesis. 
 Expression of T48I-DVAP throughout the 
nervous system in Drosophila is lethal and it 
causes premature death. To investigate the 
pathogenic mechanisms in more detail, we 
analyzed the effect of transgenic expression of the 
mutant allele in particular areas of the nervous 
system. We have shown that expression of T48I-
DVP in neurons of the larval motor system leads 
to accumulation of intracellular aggregates and 
targeted expression into the eye causes cell 
degeneration. Furthermore, expression of the 
mutant allele depletes the wt protein from its 
normal localization and recruits it into the 
aggregates. As already shown for the P56S 
mutation (e.g.(32)), this observation is consistent 
with the hypothesis that the pathogenic allele 
causes a loss-of-function of wt VAP by a 
dominant negative mechanism.  
 Dramatic ER restructuring has been reported 
in cell culture systems expressing P56S-VAP 
allele (64). Furthermore structural abnormalities in 
the ER characterized by ER fragmentation and 
Golgi cisternal dilation has been reported in motor 
neurons of patients affected by sporadic ALS (45). 
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To test whether this is also the case for the novel 
identified mutation we analyzed the ER structure 
in larval neurons expressing T48I-DVAP. We 
found that the ER in these transgenic animals 
appears fragmented, supporting the hypothesis that 
structural alterations of the ER are a consistent 
hallmark of ALS and a possible cause of motor 
neurone degeneration.  
 Finally, these neuropathological features, 
together with the up-regulation and accumulation 
of chaperone proteins in clusters, indicate a 
gradual overwhelming of the neuronal capacity to 
properly handle the pathogenic DVAPs and 
identify cellular processes that are likely to be 
crucial for ALS pathogenesis.  
 The conventional belief that ALS is 
exclusively a motor neuron disorder has been 
recently challenged by the fact that the disease is 
associated with a broad range of 
neuropsychological and behavioural deficits (62) 
and affects non-neuronal tissues such as muscle 
that may exacerbate the disease (1). In support of 
this concept, we showed that expression of T48I-
DVAP in muscle is sufficient to induce the 
accumulation of large intracellular aggregates of 
the mutant protein. This would in turn, trigger a 
local stress response, as occurs in motor neurons, 
which is characterized by sarcotubular 
fragmentation and up-regulation of HSP70. The 
results of this study show that muscle expression 
of the mutant protein can induce muscle stress and 
dysfunction independently from the consequences 
of motor neuron degeneration.  
Effect of T46I-VAP on lipid dysfunction in ALS.  
VAP proteins interact with lipid binding proteins 
such as CERT (16-18,60), a ceramide transfer 
protein required for sphingolipid synthesis (65). 
Interestingly, the T46 residue is located in a 
conserved core of VAP responsible for binding the 
FFAT motif and is essential for binding CERT 
(15,60). Therefore it is very likely that the T46I 
mutation affects the ability of VAP to interact with 
these proteins and as a consequence causes 
dysfunction in lipid metabolism. Furthermore, 
flies lacking CERT activity exhibit increased 
sensitivity to oxidative damage, motor disabilities 
and reduced life span (66) and inactivation of 
CERT in mice, causes, dilation of the ER, 
induction of UPR and impaired mitochondrial 
activity (67), all of which may play a crucial role 
in ALS pathogenesis. Indeed ALS patients 
carrying the P56S-VAPB mutation exhibit 
hyperlipidemia and increased in cholesterol and 
triglyceride levels (5) and more recent studies 
have revealed that ALS patients are more likely to 
show evidence of hyperlipidemia compared to 
controls (68). To conclude, data reported here and 
in earlier studies suggest that a correlation may 
exist between dysfunction in lipid metabolism and 
ALS pathogenesis, which warrants further 
investigation.  
In summary, based on the data presented 
here and from earlier studies, we propose a model 
for the effects of ALS-associated VAPB mutations 
and define putative pathogenic pathways (Fig 11). 
As we have shown here, mutant VAPB has a 
profound effect on the IRE1 component of UPR 
abolishing the ability of VAPB to activate this 
pathway and thereby impairing induction of ER 
chaperones and ERAD activity. This in turn 
prolongs the effects of ER stress. Accumulation of 
ubiquinitated protein aggregates reflects this 
abnormality and promotes cell death. This 
pathway would be augmented by aggregation of 
mutant VAPB and ER fragmentation. In addition, 
recruitment of VAPA and wild type VAPB to 
mutant VAPB dimmers could cause dysregulation 
of lipid trafficking and further reduce cell 
viability.    
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FIGURE LEGENDS 
Figure 1. Identification of T46I mutation in a FALS family.  A, The gene screening identified a point 
mutation T46I in VAPB. B, T46, which is indicated by an arrow head, is within the 16-amino acid 
fragment that is required for VAPB function in yeast is highlighted and is highly conserved in VAP 
proteins from yeast to human. C, Sequences of human VAPB (hVAPB) protein and its Drosophila 
orthologue DVAP were aligned by using the ClustalW v1.82 alignment program available from EMBL-
EBI. The symbol ":" represents an identity match and "." is a conserved substitution according to the 
GONNET 250 matrix. The predicted functional domains in both proteins are preserved: a transmembrane 
domain (green) at the C-terminus, a coil-coiled domain (red) in the middle and a domain (grey) at the N-
terminus showing a significant homology to the nematode Major Sperm protein (MSP).  
Figure 2. Protein properties are modified by T46I. A, COS-7 cells were transfected with the indicated 
plasmids and fixed 48 hours after transfection. The distribution of VAPB protein is indicated by GFP 
(green) and nuclei are shown with DAPI staining (blue). Scale bar of 20 µm is displayed. B, NSC-34 cells 
were harvested 48 hours after transfection with empty GFP vector or GFP VAPBs. The separation of 
Triton X-100 soluble and insoluble fraction was carried out as described by Kanekura et al., (2006). The 
fractions were blotted with anti-GFP antibody. The densitometry measurements of bands for soluble and 
insoluble VAPB was shown in C. Values are means + SEMs for 3 separate experiments. 
Figure 3. VAPB participates in the UPR. NSC-34 cells co-transfected with XBP1-Venus and RFP VAPB 
without (A) or with tunicamycin treatment (2 μg/ml, treated for 6 hours before harvested) (B). RFP and 
Venus positive cells were quantified by FACS. The proportions as a percentage of Venus positive cells in 
RFP expressing cells are shown. C, Cells stably expression wild-type or T46I-VAPB were transfected 
with Venus and RFP constructs. 24 hours after transfection, cells were harvested and analysed as in A and 
B. The p values from one-way ANOVA are 0.001 (A), 0.0035 (B) and 0.0417 (C) respectively. 
Bonferroni’s multiple comparison test was applied as a post-test and the significance values are shown in 
the graphs. D-E, The level of phosphorylated eIF2α was examined in transiently transfected cells (D) and 
in VAPB stable expression cell lines (E) with or without TG treatment (500 nM for 30 minutes before 
harvested). After correcting with the loading control, actin, the level of phosphorylated eIF2α was 
quantified. All experiments were repeated at least three times. Values are means + SEMs. * p<0.05; ** 
p<0.01; *** p<0.001 
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Figure 4. Mutant VAPB induces ubiquitin aggregate formation in both mutant protein expressing and 
neighbouring cells. A, Three days after transfected with either vector or GFP-VAPBs constructs, NSC-34 
cells were fixed and stained for endogenous ubiquitin. Examples of ubiquitin aggregates are indicated 
with arrows in each section. Ubiquitin aggregates found in GFP-negative cells are also pointed out with 
open arrow head. The number of GFP-positive cells (B) and GFP-negative cells (C) containing ubiquitin 
aggregates was counted for three independent transfections. The p values from one-way ANOVA test are 
0.0047 and 0.022 respectively. Bonferroni’s multiple comparison tests were applied as a post-test and the 
significance is shown in the graphs. Values are means + SEMs. * p<0.05; ** p<0.01. 
Figure 5. The expression of T46I-VAPB leads to greater level of cell death. NSC-34 cells which stably 
express either wild-type or T46I-VAPB were harvested for annexin V and 7-AAD staining after three day 
of culture. A, A representative experiment demonstrating the use of FACS to quantify the annexin V 
positive cells. The gating of annexin V positive cells and the percentage the gated cells are displayed. B, 
The number of annexin V and 7-AAD positive cells from four experiments were quantified. The p values 
from unpaired t-test are 0.0038 and 0.0315 for annexin V and 7-AAD, respectively C, A total of 3000 
cells were plated in each condition, whereas equal amounts of wild type and T46I-VAPB expressing cells 
were seeded in the co-culture. Cells were harvested and stained for annexin V three days after plating. 
Values are means + SEMs for 3 separate experiments. The p value from one-way ANOVA test is 0.0004 
and Bonferroni’s multiple comparison test was applied as a post-test. * p<0.05; ** p<0.01; *** p<0.001 
Figure 6. Targeted expression of T48I-DVAP in neurons induces the formation of aggregates 
immunoreactive for DVAP. A-C, Neuronal cell bodies of wt larval brains immuno-stained with an anti-
DVAP antibody (red) and anti-HRP antibody (green), a neuronal cell surface marker. DVAP is located 
underneath the cell membrane and in the cytoplasm. D-F, Immunostaining with an anti-KDEL antibody, 
a ER specific marker shows that the cytoplasmic DVAP immunoreactivity associates with the ER. G-J, 
Brains and nerve fibers of third instar larvae stained with antibodies for DVAP (red) and with antibodies 
for the neuronal cell surface marker anti-HRP (green). In controls (G), DVAP staining appears dispersed 
throughout the cytoplasm of neuronal cell bodies while in T48I-DVAP transgenic brains (H), DVAP 
immunoreactivity is associated with intracellular aggregates of variable size. Nerve fibers of control 
larvae (I) and transgenic larvae (J) were stained with anti-HRP (green) and anti-DVAP antibodies in red.  
In control nerves a faint and uniform staining for DVAP is observed while in transgenic nerves large 
aggregate strongly immunoreactive for DVAP accumulate along the nerves. Scale bars are 20 µm in (I) 
and (J) while the remaining ones are 10 µm. 
Figure 7. Transgenic expression of T48I-DVAP in the adult fly eyes causes a severe disruption of eye 
morphology. A-B, Scanning electron micrographs of controls (A) and transgenic adult fly eyes expressing 
the UAST48I-DVAP transgene under the control of the eye-specific driver, eyeless-GAL4 (B).  C and D 
are higher magnifications of A and B respectively. While the adult Drosophila eye is composed of an 
ordered array of ommatidia and interspersed bristles, transgenic eyes appear smaller, with missing or 
extra-bristles and fused ommatidia. Fused ommatidia are indicated by a white arrowhead while a black 
one points to ommatidia with extra bristles. White arrow points to missing bristles. Frontal sections of fly 
heads of control animals (E) and from flies expressing T48I-DVAP in the eye (F) are shown. Transgenic 
eyes show a severely disrupted internal morphology, cell degeneration and numerous vacuoles (see 
arrowheads for instance). Quantification of the eye surface area showing that in transgenic flies 
expressing T48I-DVAP in the eye, the surface area is, on average 50% smaller than controls (H). 
Summary of the relative frequency of eye sizes for wt and transgenes are shown in G. Scale bars in A and 
B are 200 µm. Scale bars in C and D are 100 µm.  
Figure 8. Transgenic expression of T48I-DVAP induces formation of aggregates composed of wild-type 
and mutant proteins, ER fragmentation and Hsp70 up-regulation. A-J, COS7 cells transfected with 
DVAP-FLAG (A) or Flag-DVAP and MycT48I-DVAP (B-G) were stained with antibodies specific for 
the two tags. H-M, Brains from control (H-J) and T48I-DVAP transgenic (K-M) larvae were stained for 
the ER marker, KDEL (green), and DVAP (red). N-S, Brains from control (N-P) and T48I-DVAP 
transgenic (Q-S) larvae were stained for DVAP (green) and Hsp70 (red). Scale bars of 10 µm are 
displayed.  
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Figure 9. Muscle-specific expression of T48I-DVAP causes cellular stress characterized by aggregate 
deposition, fragmentation of the sarcotubular system and Hsp70 up-regulation. A-F, Body wall muscle 
fibres from control larvae were stained for SERCA (green), an ER-sarcoplasmic reticulum and DVAP 
(red). A higher magnification of a smaller area is shown in D-F demonstrating a high degree of overlap. 
G-L, Control (G-I) and transgenic (J-L) muscles were stained for DVAP (red) and the ER marker, Boca 
(green). M-R, Control (M-O) and transgenic (P-R) muscles were stained for DVAP (red) and the Hsp70 
(green). Scale bars of 10 µm are displayed. 
Figure 10. The rare allele frequency comparison between normal and low VAPB expression groups. A, 
The positions of the six SNPs within VAPB gene are shown. The whole VAPB gene, containing six 
exons (represented with filled boxes), spans to 57.5 kb. Five SNPs most closed to each exon and one in 
the 3’UTR (represented with open box) were genotyped. B, The rare allele frequencies of the six SNPs 
are shown where the normal VAPB expression group is represented as filled bars and the low VAPB 
expression group is represented with open bars. The group of normal VAPB expression level is 
comprised of 16 SLAS, 1 FALS and 19 controls whereas the group of low VAPB expression level is 
comprised of 24SALS, 1 FALS and 2 controls. Fisher exact test was applied for each SNP and a 
significant difference of SNP rs6100067 was found (p=0.029). 
 
 











